Compare Novo Nordisk A/S (NVO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Procter & Gamble Co — how do they compare? Novo Nordisk A/S trades at $45.05 (market cap $198.57B), while Procter & Gamble Co trades at $143.2 (market cap $331.31B). The key difference: Procter & Gamble Co is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| NVO | PG | |
|---|---|---|
Market Cap | $198.57B | $331.31B |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $167.18 |
52-Week Low | $35.29 | $138.10 |
Enterprise Value | $213.37B | $357.15B |
Dividend Yield | 4.03% | 3.05% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters and maintains robust profitability with a net margin of 18.44% and ROE of 30.13%. Recent news highlights its dividend reliability and supply chain enhancements, while analyst consensus leans bullish with a $162.50 price target.
PG offers steady growth and income appeal with a 69-year dividend growth streak, but premium valuation and soft demand outlook pose near-term risks. Upside hinges on execution amid economic pressures, with support at $143 and resistance at $146.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
